2 Biotech Stocks Soar on Rare Cholesterol Treatment
The Motley Fool's health-care show Market Checkup focuses this week on cholesterol, one of America's most notable health-care concerns.
High cholesterol may not seem particularly dangerous on the surface, but when you add up the amount of at-risk Americans (71 million) and its link to the nation's most prevalent killer (heart disease, at 600,000 deaths per year), the gravity of the situation becomes quickly apparent. The good news is that pharmaceutical products and healthier lifestyles have contributed to combat this problem head-on.
In this video, health-care analysts David Williamson and Max Macaluso discuss a rare life-threatening form of high cholesterol known as homozygous familial hypercholesterolemia. This genetic disease has recently received not one but two treatment options, causing the biotechs responsible to more than double over the past year as their expensive drugs meet an an unaddressed market. Find out which stocks investors should look at and how they could keep their impressive run going.
Rising health-care costs continue to be a hotly debated topic, and even legendary investor Warren Buffett called this trend "the tapeworm that's eating at American competitiveness." To learn more about what's happening to the health care system -- and how to potentially profit from this trend -- click here for free, immediate access.
Follow David on Twitter: @MotleyDavid.
The article 2 Biotech Stocks Soar on Rare Cholesterol Treatment originally appeared on Fool.com.
David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid. Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.